IRIS
Fiorino, Gionata
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.514
AS - Asia 5.944
EU - Europa 1.981
SA - Sud America 1.458
AF - Africa 362
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 8
Totale 19.292
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.309
SG - Singapore 3.629
BR - Brasile 1.186
CN - Cina 856
VN - Vietnam 739
FI - Finlandia 415
IE - Irlanda 276
NG - Nigeria 223
DE - Germania 218
IT - Italia 189
FR - Francia 180
GB - Regno Unito 180
CA - Canada 127
HK - Hong Kong 127
NL - Olanda 114
IN - India 110
SE - Svezia 104
AR - Argentina 102
TR - Turchia 67
BD - Bangladesh 62
RU - Federazione Russa 58
IQ - Iraq 54
EC - Ecuador 51
MX - Messico 48
ID - Indonesia 44
ES - Italia 43
IL - Israele 42
UA - Ucraina 42
ZA - Sudafrica 38
BE - Belgio 35
JP - Giappone 32
CO - Colombia 31
EG - Egitto 27
PY - Paraguay 24
CL - Cile 23
SA - Arabia Saudita 23
DZ - Algeria 21
PK - Pakistan 21
AU - Australia 20
CZ - Repubblica Ceca 19
PL - Polonia 19
VE - Venezuela 19
MA - Marocco 15
KZ - Kazakistan 14
UZ - Uzbekistan 14
IR - Iran 13
KE - Kenya 12
LT - Lituania 12
PE - Perù 11
PH - Filippine 11
PT - Portogallo 11
RO - Romania 11
AZ - Azerbaigian 10
AE - Emirati Arabi Uniti 9
KR - Corea 8
MY - Malesia 8
NP - Nepal 8
TN - Tunisia 8
UY - Uruguay 8
SK - Slovacchia (Repubblica Slovacca) 7
AL - Albania 6
AT - Austria 6
GR - Grecia 6
DO - Repubblica Dominicana 5
GT - Guatemala 5
JO - Giordania 5
QA - Qatar 5
SY - Repubblica araba siriana 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BA - Bosnia-Erzegovina 4
BB - Barbados 4
BY - Bielorussia 4
GE - Georgia 4
HN - Honduras 4
JM - Giamaica 4
NO - Norvegia 4
SN - Senegal 4
BN - Brunei Darussalam 3
CH - Svizzera 3
CR - Costa Rica 3
ET - Etiopia 3
EU - Europa 3
KH - Cambogia 3
KW - Kuwait 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
BF - Burkina Faso 2
BO - Bolivia 2
BW - Botswana 2
CI - Costa d'Avorio 2
CY - Cipro 2
GA - Gabon 2
HR - Croazia 2
KG - Kirghizistan 2
LV - Lettonia 2
NI - Nicaragua 2
OM - Oman 2
TW - Taiwan 2
AM - Armenia 1
Totale 19.271
Salva come PNG Salva come JPEG
Città #
Singapore 1.727
Wilmington 1.555
Chandler 1.247
The Dalles 603
San Mateo 589
Ashburn 508
Dallas 496
Ann Arbor 437
Shanghai 423
Helsinki 412
Leawood 287
Lawrence 273
Princeton 273
Dublin 270
Ho Chi Minh City 264
Boardman 234
Benin City 222
Beijing 189
New York 186
San Jose 185
Hanoi 165
Fairfield 152
Woodbridge 152
Paris 148
Hong Kong 122
São Paulo 113
Amsterdam 93
Toronto 87
London 73
Milan 58
Rio de Janeiro 51
Los Angeles 50
Norwalk 47
Seattle 41
Kocaeli 40
Orem 40
Columbus 38
Santa Clara 36
Haiphong 34
Phoenix 33
Brussels 32
Council Bluffs 32
Monmouth Junction 28
San Diego 28
Brasília 26
Redwood City 26
Da Nang 22
Baghdad 21
Curitiba 21
Guayaquil 21
Munich 20
Frankfurt am Main 19
Belo Horizonte 18
Chennai 18
Johannesburg 18
Tokyo 18
Biên Hòa 17
Campinas 17
Pune 17
Abbiategrasso 16
Cambridge 16
Falkenstein 16
Montreal 15
Brno 14
Chicago 14
Hải Dương 14
Porto Alegre 14
Cairo 13
Ninh Bình 13
Warsaw 13
Erbil 12
Guarulhos 12
Nairobi 12
Rome 12
Buffalo 11
Can Tho 11
Dhaka 11
Goiânia 11
Jakarta 11
Medellín 11
Quito 11
Tashkent 11
Thái Bình 11
Brooklyn 10
Cape Town 10
Houston 10
Istanbul 10
Manchester 10
Moscow 10
Phủ Lý 10
Santo André 10
Baku 9
Boston 9
Des Moines 9
Lisbon 9
Mumbai 9
Riyadh 9
Sacramento 9
Salvador 9
Santiago 9
Totale 12.838
Salva come PNG Salva come JPEG
Nome #
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications 339
A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience. 145
Adalimumab in ulcerative colitis: hypes and hopes 134
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis 128
A Prospective Comparison Between 1.5t Magnetic Resonance and 3t Magnetic Resonance in Ileo-Colonic Crohn's Disease: A Single Center Experience 125
Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease 118
Adalimumab is effective in achieving clinical and endoscopic long-term deep remission : a case report 117
New Drug Delivery Systems in Inflammatory Bowel Disease: MMX (TM) and Tailored Delivery to the Gut 116
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 115
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies 114
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study 109
Adalimumab in Crohn's disease : tips and tricks after 5 years of clinical experience 108
Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease 106
Accuracy of a New Fujiifilm Blue Light Prototype in Predicting the Histology of Subcentimetric Polyps 106
Risk of postoperative recurrence and postoperative management of Crohn's disease 105
Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects? 104
A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis 103
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study 101
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD 101
A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis 99
Balanced Propofol Sedation (BPS) Administered by Non-Anesthesiologists vs Midazolam Alone for Endoscopic Procedure in Patients With IBD: A Single Center Open-Label Trial 97
Impact of Medications on Radiologic Disease Activity and Bowel Damage in Crohn's Disease: A Prospective Longitudinal MRI Study 95
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy 95
Perception of reproductive health in women with inflammatory bowel disease 94
MFSD2A Promotes Endothelial Generation of Inflammation-resolving Lipid Mediators and Reduces Colitis in Mice 94
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 94
ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease Part 2. IBD scores and general principles and technical aspects 94
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. 94
Emerging biologics in the treatment of inflammatory bowel disease : what is around the corner? 93
Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience 93
Effect of Immunosuppression on Immune Response to Pneumococcal Vaccine in Inflammatory Bowel Disease: A Prospective Study 93
The bacterial sensor Triggering Receptor Expressed on Myeloid cells 2 (TREM-2) is a crucial pathogenic mediator in inflammatory bowel disease (IBD) 93
A PROLONGED FOLLOW-UP ON THE EFFICACY AND SAFETY OF INFLIXIMAB BIOSIMILAR CT-P13 IN IBD ACROSS ITALY: THE PROSIT COHORT 92
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 91
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease : a prospective study 91
A PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY ASSESSING THE EFFECTIVENESS OF BUDESONIDE MMX® FOR MILD-TO-MODERATE ULCERATIVE COLITIS 90
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 89
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease 89
Are Surgical Rates Decreasing in the Biological Era In IBD? 89
Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? 87
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes 87
‘Quality of care’ standards in inflammatory bowel disease: A systematic review 87
Effect of tumour necrosis factor antagonists on avoiding surgery in stricturing Crohn's disease: a tertiary centre real-life experience 87
Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study 86
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease 86
Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas 85
Contrast-enhancement at magnetic resonance enterography does not differentiate between fibrosis and inflammation in Crohn's disease: a prospective cohort study 85
OP018 High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signalling 85
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 85
Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease : a case-matched analysis 85
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease A Systematic Review and Meta-Analysis of Randomized Controlled Trials 84
Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond? 83
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 83
Adalimumab for the treatment of pediatric Crohn's disease 82
Familial aggregation in inflammatory bowel disease: Is it genes or environment? 82
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease 82
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target 81
Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome 80
Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation 80
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan 80
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? 79
JAK inhibitors: Novel developments in management of ulcerative colitis 79
Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases 79
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease 78
Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease 78
Emerging therapeutic targets and strategies in Crohn's disease 77
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients 77
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials 77
VAGUS NERVE STIMULATION REDUCES DISEASE ACTIVITY AND MODULATES SERUM AND AUTONOMIC BIOMARKERS IN BIOLOGICREFRACTORY CROHN'S DISEASE 77
A HEALTH TECHNOLOGY-RELATED COST DESCRIPTION CONCERNING ITALIAN IBD CENTRES DEALING WITH CROHN'S DISEASE: RESULTS FROM SOLE STUDY 77
Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply 76
Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy 76
Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients 75
Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study 74
Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease 74
Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease 74
Infliximab Inhibits Mucosal Pathological Angiogenesis in Crohn's Disease 74
The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges 74
Commentary: adjunct antibiotic combination therapy for ulcerative colitis - is it time to investigate Fusobacterium varium? 73
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? 73
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy 73
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target 72
Dose Optimization Is Effective in Patients With Ulcerative Colitis Losing Response to Infliximab: A Collaborative Multicentre Retrospective Study 72
ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment 72
y ANTIBODIES TO INFLIXIMAB IN PATIENTS TREATED WITH EITHER THE REFERENCE BIOLOGIC OR THE BIOSIMILAR CT-P13 SHOW IDENTICAL REACTIVITY TOWARDS BIOSIMILARS CT-P13 AND SB2 IN INFLAMMATORY BOWEL DISEASE 72
Clinical Utility of the LeMann Index and Rutgeerts Score to Predict Postoperative Course of Crohn's Disease: A Retrospective Single-Center Cohort Study 72
The Role of Magnetic Resonance Imaging in Detecting Intestinal Fibrosis in Crohn's Disease 72
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy 71
Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease 71
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile 71
Videocapsule endoscopy in portal hypertension: Seek till you find 71
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis 71
Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience 71
Safety of a (H1N1)V Vaccine in patients with inflammatory bowel disease treated with immunomodulators and biologicals 71
Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group 71
Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey 70
Psychological Functioning of Patients With Inflammatory Bowel Disease 70
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 70
Biological Agents for Moderately to Severely Active Ulcerative Colitis A Systematic Review and Network Meta-analysis 70
Different Segmental Transit Time (TT) Through the Small Bowel May Affect Wireless Capsule (WC) Endoscopy 70
Totale 8.959
Salva come PNG Salva come JPEG
Categoria #
all - tutte 135.312
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 135.312
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021680 0 0 0 0 0 0 0 0 0 337 15 328
2021/20221.513 99 15 65 306 12 8 64 197 152 203 310 82
2022/20233.348 616 152 388 350 208 281 16 256 544 324 168 45
2023/20241.934 202 151 383 92 56 257 101 117 34 42 168 331
2024/20252.711 60 61 25 55 29 324 130 305 350 741 296 335
2025/20267.062 1.042 550 724 1.037 287 252 1.963 442 408 357 0 0
Totale 19.554